NCT05973149View on ClinicalTrials.gov

Trial of QLH12016 in Patients With Metastatic Castration Resistant Prostate Cancer

PHASE1Not yet recruitingINTERVENTIONAL
Enrollment

108

Participants

Timeline

Start Date

August 31, 2023

Primary Completion Date

August 31, 2025

Study Completion Date

January 1, 2026

Conditions
Prostate Cancer
Interventions
DRUG

QLH12016

according to the scheme description

Trial Locations (2)

100034

Department of Urology, Peking University First Hospital, Beijing

210008

Department of Urology, Drum Tower Hospital, Nanjing University School of Medicine, Nanjing

All Listed Sponsors
lead

Qilu Pharmaceutical Co., Ltd.

INDUSTRY

NCT05973149 - Trial of QLH12016 in Patients With Metastatic Castration Resistant Prostate Cancer | Biotech Hunter | Biotech Hunter